Physician profile
Devaki Siva
NPI 1982823290
$5,394.29
in general payments reported to CMS, 2019-2025
57 companies · $508 in 2025
The $508 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,277 · 2020: $448 · 2021: $35.87 · 2022: $174 · 2023: $543 · 2024: $2,409 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,087 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,086.60 |
| Education | $372.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $556.66 | 2019-2024 | Lynparza, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $490.24 | 2019-2025 | |
| Pfizer INC. | $363.07 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $339.63 | 2019-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $307.78 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Genentech USA, INC. | $243.12 | 2019-2024 | Venclexta, Alecensa, Tecentriq |
| Daiichi Sankyo INC. | $205.24 | 2019-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $152.65 | 2019-2024 | Keytruda, Lynparza |
| Novocure INC. | $133.31 | 2024 | Optune |
| Janssen Biotech, INC. | $131.32 | 2019-2024 | Tecvayli, Talvey, Darzalex |
| Gilead Sciences, INC. | $131.23 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.83 | 2020-2025 | |
| Seagen INC. | $129.23 | 2023-2025 | Adcetris, Padcev |
| Amgen INC. | $121.58 | 2019-2023 | Lumakras |
| Lilly USA, LLC | $120.43 | 2024 | Verzenio, Jaypirca |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $119.45 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Astellas Pharma US INC | $117.66 | 2019-2025 | Xtandi, Vyloy |
| Celgene Corporation | $115.38 | 2019-2024 | Reblozyl |
| Rigel Pharmaceuticals, INC. | $105.18 | 2019-2024 | Tavalisse, Rezlidhia |
| Glaxosmithkline, LLC. | $98.98 | 2020-2024 | Jemperli, Zejula, Ojjaara |
| Pharmaessentia USA Corporation | $97.41 | 2024 | Besremi |
| Taiho Oncology, INC. | $84.63 | 2019-2025 | |
| Agios Pharmaceuticals, INC. | $76.39 | 2019-2020 | |
| Emd Serono, INC. | $75.00 | 2019-2024 | |
| Puma Biotechnology, INC. | $69.13 | 2019-2025 | |
| Eisai INC. | $60.50 | 2019-2023 | |
| Abbvie INC. | $60.25 | 2019-2025 | |
| Array Biopharma INC | $57.62 | 2023-2024 | Lorbrena, Mektovi, Braftovi |
| Exelixis INC. | $44.16 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $43.63 | 2020-2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $43.56 | 2023-2024 | |
| Foundation Medicine, INC. | $37.36 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $36.34 | 2024 | Libtayo |
| Pharmacosmos Therapeutics INC. | $31.65 | 2024 | Monoferric, Cosela |
| Genzyme Corporation | $31.30 | 2019 | |
| Karyopharm Therapeutics INC. | $30.52 | 2020-2024 | Xpovio |
| Sobi, INC | $30.26 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.91 | 2024 | Gilotrif |
| Tersera Therapeutics LLC | $25.26 | 2019 | |
| Geron Corporation | $25.01 | 2025 | Rytelo |
| Tempus Ai, INC | $23.35 | 2024 | |
| Azurity Pharmaceuticals, INC. | $23.00 | 2024 | Vivimusta |
| Spectrum Pharmaceuticals INC. | $22.53 | 2024 | Rolvedon |
| Genmab U.S., INC. | $20.12 | 2024 | Epkinly |
| Kedrion Biopharma, INC. | $20.10 | 2024 | Rhogam Ultra-Filtered Plus, Kedrab, Albuked |
| Jazz Pharmaceuticals INC. | $19.72 | 2024 | |
| Immunocore Limited | $19.67 | 2024 | Kimmtrak |
| Kyowa Kirin, INC. | $18.32 | 2020 | |
| Beigene USA, INC. | $16.61 | 2024 | Brukinsa |
| Sumitomo Pharma America, INC. | $16.06 | 2024 | Orgovyx |
| Coherus Oncology, INC. | $16.01 | 2020 | |
| Amag Pharmaceuticals, INC. | $15.81 | 2019 | |
| Horizon Therapeutics Plc | $15.42 | 2020 | |
| Adc Therapeutics America, INC. | $14.10 | 2024 | |
| Blueprint Medicines Corporation | $12.45 | 2021 | |
| Dova Pharmaceuticals | $11.66 | 2019 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devaki Siva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.